NEW YORK – Agios Pharmaceuticals said on Monday that it has partnered with PerkinElmer Genomics on a genetic testing program for patients with suspected hereditary anemias.
Testing will be performed using a next-generation sequencing-based panel comprising more than 50 genes and disorders known to cause hereditary anemias, such as pyruvate kinase deficiency.